Iron Deficiency Anemia Therapy Market - By Product Type (Oral Iron, Intravenous [IV] Iron), Therapy Areas (Inflammatory Bowel Disease, Renal, Oncology), Age Group (Adults, Pediatric), Distribution Channel- Global Forecast 2024 – 2032

Iron Deficiency Anemia Therapy Market - By Product Type (Oral Iron, Intravenous [IV] Iron), Therapy Areas (Inflammatory Bowel Disease, Renal, Oncology), Age Group (Adults, Pediatric), Distribution Channel- Global Forecast 2024 – 2032

Iron Deficiency Anemia Therapy Market Size

Iron Deficiency Anemia Therapy Market size was valued at around USD 4.3 billion in 2023 and is estimated to grow at 6.5% CAGR from 2024 to 2032. Iron deficiency anemia is a condition characterized by a lack of adequate healthy red blood cells due to insufficient iron levels. Iron is essential for producing hemoglobin, the protein in red blood cells that carries oxygen throughout the body. Iron levels are low, the body cannot produce enough hemoglobin, leading to symptoms such as fatigue, weakness, pale skin, shortness of breath, and dizziness.

To get key market trends

  Download Free Sample

The rising prevalence of iron deficiency anemia is a significant driver for the market. For instance, according to the World Health organization, in 2023, it is estimated that globally 40% of children aged 6–59 months, 37% of pregnant women, and 30% of women aged 15–49 years are affected by anemia. This resulted into an urgent need for increased investment in effective treatments and public health interventions to combat iron deficiency anemia. It highlights the growing necessity for developing and implementing effective anemia therapies and strategies.
 

What are the growth opportunities in this market?

 Download Free Sample

Furthermore, increasing awareness and diagnosis, advancements in treatment options, growing geriatric population, are the promoting factors advancing the growth of the market.

Iron Deficiency Anemia Therapy Market Trends

Iron deficiency anemia remains a prevalent and significant health concern worldwide, affecting millions of individuals, including children, pregnant women, and women of reproductive age. There have been considerable advancements in the treatment options available, aimed at improving efficacy, minimizing side effects, and enhancing patient adherence. These innovations offer better management and outcomes for those affected by iron deficiency anemia, addressing the diverse needs of this widespread condition.

• Newer oral iron supplements, such as heme iron polypeptides and ferric maltol, are designed to enhance absorption and reduce gastrointestinal side effects compared to traditional iron salts. These formulations improve iron uptake and minimize side effects by releasing iron gradually in the intestine, leading to better absorption and increased patient comfort.
• Innovations such as ferric carboxymaltose, iron isomaltoside, and ferumoxytol provide higher doses of iron in a single infusion, reducing the frequency of treatments and improving patient compliance. Advanced formulations have also been developed to minimize the risk of allergic reactions and other side effects, making IV iron therapy safer for a broader range of patients.
• Point-of-care testing, which is estimated to reach USD 78.3 billion by 2032, and non-invasive technologies such as transcutaneous bilirubin meters and hematocrit measurement devices are pivotal in improving the identification and management of iron deficiency anemia (IDA). These innovations enable timely assessment of hemoglobin levels and iron status, enhancing diagnostic accuracy and patient care efficiency in clinical settings, thereby contributing to market growth.

Iron Deficiency Anemia Therapy Market Analysis

Learn more about the key segments shaping this market

 Download Free Sample

Based on type, the market is divided into oral iron and intravenous (IV) iron. The intravenous (IV) iron therapy segment of the market is forecasted to reach USD 3 billion by 2032 owing to its rapid growth.

• Intravenous (IV) administration facilitates swift replenishment of iron, particularly advantageous in severe cases of iron deficiency anemia where prompt correction is crucial to mitigate complications such as cardiovascular strain or worsening symptoms such as fatigue and shortness of breath.
• By bypassing the digestive system, intravenous therapy minimizes common gastrointestinal side effects associated with oral iron supplementation, such as nausea, constipation, and abdominal discomfort.
• Further, intravenous iron therapy is highly effective for patients with chronic conditions (such as inflammatory bowel disease, chronic kidney disease, or gastrointestinal disorders), that impair oral iron absorption. Thus, contributing to an increasing demand for intravenous iron therapy in the market.

Learn more about the key segments shaping this market

 Download Free Sample

Based on therapy areas, the iron deficiency anemia therapy market is bifurcated into inflammatory bowel disease, renal, obstetrics and gynecology, congestive heart failure (CHF), oncology, and other therapy areas. The inflammatory bowel disease segment accounted for USD 974.1 million in 2023.

• Inflammatory bowel disease (IBD) often leads to chronic inflammation and intestinal damage, impairing the absorption of nutrients, including iron. Iron deficiency anemia therapy, particularly intravenous (IV) administration, ensures efficient delivery of iron directly into the bloodstream, bypassing the compromised gut absorption and effectively replenishing iron stores.
• IV iron therapy can be integrated into overall IBD treatment strategies, including biologic therapies and immunosuppressants. By addressing iron deficiency, healthcare providers can enhance the effectiveness of IBD treatments and support disease control and symptom management.
• Additionally, effective management of iron deficiency anemia in IBD patients can lead to improved quality of life outcomes. By reducing anemia-related symptoms such as fatigue, weakness, and cognitive impairment, IV iron therapy supports patients in maintaining their daily activities and overall well-being. Thus, propelling the growth of the market.

Based on age group, the iron deficiency anemia therapy market is segmented into adults, pediatric, and geriatric. The adult of the market is forecasted to reach USD 4.6 billion by 2032.

• Addressing iron deficiency can alleviate symptoms such as fatigue and weakness, which are common in adults and often attributed to anemia. By restoring iron levels, therapy helps improve overall energy levels and vitality, enhancing daily functioning and quality of life.
• Iron is essential for cognitive function and brain health. Treating iron deficiency anemia in adults may support cognitive function, including memory and concentration, potentially mitigating cognitive decline associated with anemia.
• Further, maintaining optimal iron levels through therapy supports long-term health and reduces the risk of developing chronic conditions associated with untreated iron deficiency anemia. This includes cardiovascular diseases, neurological disorders, and other health complications. Thus, escalating the growth of the market.

Based on distribution channel, the iron deficiency anemia therapy market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment is forecasted to reach USD 3.6 billion by 2032.

• Hospital pharmacists are highly trained in managing complex medical therapies, including iron supplementation regimens tailored to individual patient needs. They ensure appropriate dosing, monitor for potential drug interactions, and provide guidance on administration techniques.
• Hospitals can administer intravenous iron therapy, which is sometimes necessary for patients who cannot tolerate or absorb oral iron supplements effectively. This route of administration allows for rapid correction of severe anemia and is closely monitored to ensure safety.
• Further, hospital pharmacies provide regular monitoring of iron levels and response to therapy, adjusting treatment as needed based on clinical assessments. This proactive approach helps prevent complications and ensures timely intervention if therapy adjustments are required. Thus, driving the growth of the market

Looking for region specific data?

 Download Free Sample

The growth of the iron deficiency anemia therapy market in the U.S., projected to reach USD 2.8 billion by 2032.

• The U.S. healthcare system is characterized by its advanced infrastructure, including state-of-the-art hospitals, specialized clinics, and a robust network of healthcare providers. This infrastructure supports comprehensive diagnostic capabilities, specialized treatment options, and access to cutting-edge therapies for managing IDA.
• The U.S. is a global leader in biomedical research and pharmaceutical innovation. Numerous pharmaceutical companies, research institutions, and academic centers conduct extensive research on iron deficiency anemia, leading to the development of novel therapies, advanced diagnostic tools, and improved treatment protocols.

The iron deficiency anemia therapy market in UK is expected to experience significant and promising growth from 2024 to 2032.

• The UK maintains stringent quality standards and regulatory oversight through organizations such as the Medicines and Healthcare products Regulatory Agency (MHRA). These regulations ensure the safety, efficacy, and quality of iron supplementation products and therapeutic interventions used in the management of iron deficiency anemia.

Japan iron deficiency anemia therapy market is anticipated to witness lucrative growth between 2024 – 2032.

• Japanese institutions are actively engaged in clinical research and biomedical studies focused on iron metabolism, anemia management, and therapeutic advancements. This research excellence contributes to the development of evidence-based treatment guidelines, novel therapies, and improved patient care practices for individuals with iron deficiency anemia.

The iron deficiency anemia therapy market in Saudi Arabia is expected to experience significant and promising growth from 2024 to 2032.

• The Saudi Arabian government prioritizes healthcare as a key sector for development, investing in healthcare infrastructure, medical research, and healthcare services. This commitment enhances accessibility to healthcare services and supports advancements in IDA diagnosis and treatment.

Iron Deficiency Anemia Therapy Market Share

The iron deficiency anemia therapy sector is competitive in nature, with a mix of major global and smaller to medium-sized companies competing for market share. A pivotal aspect of market strategy involves the continual introduction of innovative products leveraging diverse technologies. The prominent market players in command considerable influence, often driving forward advancements through substantial investments in research and development. These leading companies play a pivotal role in shaping the market's trajectory. In addition to research and development efforts, strategic alliances, acquisitions, and mergers are instrumental in fortifying market positions and expanding the global footprint of prominent market players. These strategic moves are particularly crucial due to evolving regulatory landscapes in the market.

Iron Deficiency Anemia Therapy Market Companies

Some of the eminent market participants operating in the iron deficiency anemia therapy industry include

• Abbott Laboratories
• AbbVie Inc.
• AdvaCare Pharma
• Akebia Therapeutics, Inc.
• Bayer AG
• Covis Pharma GmbH
• CSL Limited
• F. Hoffmann-La Roche Ltd.
• GSK plc
• Johnson & Johnson
• Novartis AG
• PHARMACOSMOS A/S
• Pfizer Inc.
• Sanofi
• SK Capital Partners
• Zydus Lifesciences Limited

Iron Deficiency Anemia Therapy Industry News

• In March 2024, Akebia Therapeutics, Inc. announced FDA approval of Vafseo (vadadustat) tablets for treating anemia in adults with chronic kidney disease (CKD). This approval marks a significant advancement in CKD treatment options, addressing a critical need for managing anemia associated with dialysis.
• In March 2024, CSL announced Health Canada's authorization of Ferinject (ferric carboxymaltose) for intravenous treatment of iron deficiency anemia in adults and pediatric patients aged one year and older, when oral iron is ineffective or not tolerated. Additionally, it is approved for treating iron deficiency in adults with heart failure. This approval expands treatment options for patients facing challenges with oral iron therapy and underscores advancements in managing iron-related conditions.

The iron deficiency anemia therapy market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments

Click here to Buy Section of this Report

Market, By Product Type

• Oral iron
• Intravenous (IV) iron

Market, By Therapy Areas

• Inflammatory bowel disease
• Renal
• Obstetrics and gynecology
• Congestive heart failure (CHF)
• Oncology
• Other therapy areas

Market, By Age Group

• Adults
• Pediatric
• Geriatric

Market, By Distribution Channel

• Hospital pharmacy
• Retail pharmacy
• Online pharmacy

The above information is provided for the following regions and countries

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America 
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa